598 Bemcentinib + pembrolizumab show promising efficacy in metastatic NSCLC harbouring mutations associated with poor prognosis: exploratory sub-analysis from the BGBC008 trial (NCT03184571)

• Michael Chisamore,
• Noelly Madeleine,
• Austin Rayford,
• Gro Gausdal,
• David R Micklem,
• Magnus Blø,
• Dina Alzhanova,
• Josephine Amalia Taverna,
• Chia-Nung Hung,
• Rolf A Brekken,
• Claudia Gorcea-Carson,
• Cristina Oliva,
• Nigel McCracken

Affiliations

Michael Chisamore

4Merck and Co., Inc., Rahway, NJ, USA

Noelly Madeleine

12BerGenBio ASA, Bergen, Norway

Austin Rayford

12BerGenBio ASA, Bergen, Norway

Gro Gausdal

1BerGenBio ASA, Bergen, Norway

David R Micklem

1BerGenBio ASA, Bergen, Norway

Magnus Blø

1BerGenBio ASA, Bergen, Norway

Dina Alzhanova

3University of Texas Southwestern Medical Center, Dallas, TX, USA

Josephine Amalia Taverna

4University of Texas Health Science Center, San Antonio, TX, USA

Chia-Nung Hung

4University of Texas Health Science Center, San Antonio, TX, USA

Rolf A Brekken

3University of Texas Southwestern Medical Center, Dallas, TX, USA

Claudia Gorcea-Carson

6BerGenBio Ltd, Oxford, Oxfordshire, UK

Cristina Oliva

6BerGenBio Ltd, Oxford, Oxfordshire, UK

Nigel McCracken

6BerGenBio Ltd, Oxford, Oxfordshire, UK